We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+32.57%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$163M
AUM Growth
+$86.2M
Cap. Flow
+$60.7M
Cap. Flow %
37.31%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$60.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
1
Phathom Pharmaceuticals
PHAT
$708M
$68.1M 41.83%
2,067,861
– –
PCVX icon
2
Vaxcyte
PCVX
$7.81B
$59.7M 36.67%
+1,887,478
New +$60.7M
MRUS
3
DELISTED
Merus
MRUS
$25.7M 15.82%
1,600,000
– –
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$9.25M 5.68%
1,570,000
– –

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q2 2020 Portfolio in Review

As of Q2 2020, Medicxi Ventures Management held 4 positions worth $163M, up 113% from $76.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management deployed $60.7M of net new capital in Q2 2020, opening 1 new position. Its largest new stake was Vaxcyte: 1,887,478 shares worth $59.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's largest Q2 2020 buy was Vaxcyte: 1,887,478 shares worth $59.7M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $163M portfolio in Q2 2020.
  • Medicxi Ventures Management opened 1 new position and closed 0 in Q2 2020.
  • Medicxi Ventures Management's portfolio value rose 113% quarter-over-quarter to $163M.

Based on Medicxi Ventures Management's 13F filing for Q2 2020, filed 7 Aug 2020.